0.8049
전일 마감가:
$0.8439
열려 있는:
$0.83
하루 거래량:
957.47K
Relative Volume:
0.72
시가총액:
$75.54M
수익:
-
순이익/손실:
$-93.61M
주가수익비율:
-0.3815
EPS:
-2.11
순현금흐름:
$-71.16M
1주 성능:
+2.09%
1개월 성능:
-18.68%
6개월 성능:
-28.77%
1년 성능:
-34.56%
Immunic Inc Stock (IMUX) Company Profile
명칭
Immunic Inc
전화
(332) 255-9818
주소
1200 AVENUE OF THE AMERICAS, NEW YORK
IMUX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
IMUX
Immunic Inc
|
0.8049 | 75.54M | 0 | -93.61M | -71.16M | -2.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-25 | 개시 | William Blair | Outperform |
2024-11-25 | 개시 | H.C. Wainwright | Buy |
2024-09-09 | 재개 | Leerink Partners | Outperform |
2024-08-27 | 개시 | B. Riley Securities | Buy |
2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
2022-09-19 | 재개 | H.C. Wainwright | Buy |
2021-04-15 | 개시 | Aegis Capital | Buy |
2021-03-24 | 개시 | JMP Securities | Mkt Outperform |
2020-10-02 | 개시 | SVB Leerink | Outperform |
2020-08-26 | 개시 | Piper Sandler | Overweight |
2020-08-07 | 재개 | ROTH Capital | Buy |
2020-07-20 | 개시 | BMO Capital Markets | Outperform |
2020-06-05 | 개시 | Wedbush | Outperform |
2020-05-11 | 개시 | H.C. Wainwright | Buy |
2020-03-25 | 개시 | ROTH Capital | Buy |
2019-07-11 | 개시 | Chardan Capital Markets | Buy |
모두보기
Immunic Inc 주식(IMUX)의 최신 뉴스
Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Brokerages - Defense World
Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted (NASDAQ:IMUX) - Seeking Alpha
Millennium Management LLC Has $580,000 Stake in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic completes Phase 3 multiple sclerosis trial enrollmentICYMI - Proactive financial news
Immunic Therapeutics reaches major milestone with completion of ENSURE Trial Enrollment - Proactive financial news
Immunic at Jefferies Conference: Promising MS Drug Insights By Investing.com - Investing.com South Africa
Immunic at Jefferies Conference: Promising MS Drug Insights - Investing.com Australia
Small cap wrap: Midnight Sun Mining, Standard Uranium, Immunic, ReconAfrica... - Proactive Investors
Market movers: Tesla, Verint, PVH, Immunic... - Proactive financial news
Immunic (IMUX) Receives Continued 'Buy' Rating from D. Boral Cap - GuruFocus
Immunic (IMUX) Receives Continued 'Buy' Rating from D. Boral Capital | IMUX Stock News - GuruFocus
Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials - Proactive financial news
Immunic Completes Enrollment in 2 Phase 3 Studies in Relapsing Multiple Sclerosis - marketscreener.com
IMUX: Promising Results of Vidofludimus Calcium in Multiple Scle - GuruFocus
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS - The Malaysian Reserve
Immunic Announces Completion of Enrollment for Both Phase 3 ENSU - GuruFocus
IMUX Completes Enrollment for Phase 3 Trials in Multiple Sclerosis | IMUX Stock News - GuruFocus
Top Executives Make Bold Moves with Major Immunic Stock Purchases! - TipRanks
Immunic Approves Equity Plan Amendment at Annual Meeting - TipRanks
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering | IMUX Stock News - GuruFocus
Immunic Announces Closing Of Oversubscribed $65 Million Underwritten Public Offering - marketscreener.com
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - Longview News-Journal
Immunic raises $65M in public offering to fund clinical trials - Proactive financial news
Immunic to Participate in Investor, Scientific and Industry Conf - GuruFocus
Immunic to Participate in Investor, Scientific and Industry Conferences in June - The Malaysian Reserve
Immunic releases June conference schedule - Proactive financial news
Immunic to Participate in Investor, Scientific and Industry Conferences in June | IMUX Stock News - GuruFocus
Immunic Announces $65 Million Public Offering - TipRanks
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Eastern Progress
Immunic Inc. prices $65 million public offering By Investing.com - Investing.com South Africa
Immunic (NASDAQ:IMUX) Price Target Lowered to $10.00 at D. Boral Capital - Defense World
Immunic (IMUX) Launches $65M Public Offering, Shares Drop - GuruFocus
Immunic Tumbles After Pricing $65 Million Offering of Warrants - marketscreener.com
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Un - GuruFocus
Small cap wrap: Fineqia, Synchronoss, Santacruz Silver, Immunic... - Proactive financial news
Immunic (IMUX) Receives Target Price Adjustment from D. Boral Ca - GuruFocus
Immunic (IMUX) Receives Target Price Adjustment from D. Boral Capital | IMUX Stock News - GuruFocus
Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering - GuruFocus
Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering | IMUX Stock News - GuruFocus
Immunic (IMUX) Launches Public Offering with Warrant Options | I - GuruFocus
Immunic shares fall 12% after pricing of $65 million underwritten public offering to fund trials - Seeking Alpha
Immunic to raise up to $65M in underwritten public offering - Proactive Investors
Immunic (IMUX) Launches Public Offering with Warrant Options | IMUX Stock News - GuruFocus
Immunic Announces Pricing Of Oversubscribed $65 Million Underwritten Public Offering - marketscreener.com
Immunic Inc. prices $65 million public offering - Investing.com
Immunic, Inc. Announces Proposed Public Offering - Longview News-Journal
Immunic launches public offering of warrants to fund clinical trials; shares down - MSN
Immunic slides on planned equity raise - TradingView
Immunic (IMUX) Launches Public Offering with Pre-Funded and Warr - GuruFocus
Immunic announces public offering of warrants to fund trials By Investing.com - Investing.com India
Immunic (IMUX) Launches Public Offering with Pre-Funded and Warrants | IMUX Stock News - GuruFocus
Immunic Inc (IMUX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immunic Inc 주식 (IMUX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
Rudick Richard Alan | Director |
Nov 12 '24 |
Buy |
1.15 |
87,300 |
100,369 |
87,300 |
자본화:
|
볼륨(24시간):